Both in Pharmaceuticals
DiaMedica Therapeutics vs ARS Pharmaceuticals
Over the past year DMAC returned +18.7% and SPRY returned −54.7%; their daily moves had a correlation of 0.27.
DMAC +18.7% SPRY −54.7%Growth of $1, one year, split-adjusted
| Metric | DMAC | SPRY |
|---|---|---|
| Price | $8.20 | $4.40 |
| Market cap | $442.2M | $437.6M |
| Today | −1.44% | +6.54% |
| 1 month | +28.3% | −25.3% |
| 6 months | +23.5% | −43.7% |
| Year to date | +3.0% | −62.2% |
| 1 year | +18.2% | −55.1% |
| Revenue growth (YoY) | — | +114.2% |
| Gross margin | — | 61.8% |
| Net margin | — | −185.2% |
| P/E (TTM) | — | — |
| Price / sales | — | 3.7× |
| Net cash | $43.5M | -$27.8M |
| Dividend yield | — | — |
| Volatility (60d) | 43.2% | 70.0% |
| Short % of float | 22.6% | 47.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).